Incyte Total Stockholder Equity Over Time
| INCY Stock | USD 80.48 0.10 0.12% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Incyte Performance and Incyte Correlation. Incyte |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.29) | Earnings Share 0.09 | Revenue Per Share 18.968 | Quarterly Revenue Growth 0.238 | Return On Assets (0) |
The market value of Incyte is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte's value that differs from its market value or its book value, called intrinsic value, which is Incyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte's market value can be influenced by many factors that don't directly affect Incyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Stockholder Equity Analysis
Compare Incyte and related stocks such as Alnylam Pharmaceuticals, United Therapeutics, and Ultragenyx Total Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALNY | (4.6 M) | 118 M | 134.1 M | 270.3 M | 936.3 M | 1.3 B | 920.2 M | 1.8 B | 1.3 B | 1.4 B | 1 B | 588.2 M | (158.2 M) | (220.6 M) | (209.6 M) |
| UTHR | 16.7 M | 948.5 M | 1.1 B | 1.3 B | 1.3 B | 1.6 B | 1.9 B | 2.1 B | 2.8 B | 2.8 B | 3.4 B | 4 B | 4.8 B | 6 B | 6.3 B |
| RARE | 10.6 M | 10.6 M | 84.3 M | 50.1 M | 184.9 M | 531.1 M | 474 M | 383.5 M | 608.9 M | 653.8 M | 1.2 B | 922.6 M | 352.5 M | 275.4 M | 481.1 M |
| APLS | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 13.2 M | 35 M | 23.8 M | 148.9 M | 161 M | 34.2 M | 204.6 M | 198.7 M | 169.9 M | 194.5 M | 118.8 M |
| BGNE | (38.7 M) | (38.7 M) | (38.7 M) | (38.7 M) | 25.8 M | (101.8 M) | 352.9 M | 684.2 M | 1.8 B | 978.4 M | 3.9 B | 6.2 B | 4.4 B | 3.5 B | 2.2 B |
| BMRN | 29.4 M | 773 M | 1 B | 1.3 B | 1.5 B | 2.4 B | 2.8 B | 2.8 B | 3 B | 3.1 B | 4.1 B | 4.3 B | 4.6 B | 5 B | 5.2 B |
| ARWR | (2.6 M) | 10 M | 27.5 M | 166.5 M | 110.2 M | 95.6 M | 81.4 M | 95.8 M | 244.6 M | 461.8 M | 408.8 M | 106 M | 271.3 M | 312 M | 327.6 M |
| IONS | 1.7 M | 171.4 M | 182.8 M | 378.4 M | 257.8 M | 200.8 M | 99.6 M | 330.9 M | 1 B | 1.5 B | 843 M | 772 M | 573 M | 386.7 M | 265.7 M |
| AXSM | (2 M) | (2 M) | (2 M) | (2 M) | (3.2 M) | (18.8 M) | (47.6 M) | (76.6 M) | (107.6 M) | (175.9 M) | (278.8 M) | (409.2 M) | 109.6 M | 191 M | 200.5 M |
| SRPT | 2.1 M | 31 M | 123.7 M | 247.2 M | 247.7 M | 190.3 M | 336.7 M | 789.2 M | 1 B | 818.2 M | 761.8 M | 928 M | 384.9 M | 859.3 M | 902.3 M |
| ACAD | (22.5 M) | 23.4 M | 85 M | 182.1 M | 309.5 M | 199.8 M | 518.4 M | 335.3 M | 479.1 M | 699.1 M | 627 M | 540.9 M | 400.4 M | 431.8 M | 232.8 M |
| FOLD | (5.3 M) | 29.6 M | 69.2 M | 45.8 M | 122.2 M | 347.8 M | 360.2 M | 352.9 M | 342.9 M | 476.4 M | 286.4 M | 307.4 M | 123 M | 160.2 M | 168.7 M |
| DNLI | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | (15.6 M) | 254.5 M | 465.8 M | 546.8 M | 394.9 M | 1.2 B | 962.3 M | 1 B | 1 B | 712.9 M |
| ARGX | 10.2 M | 27.9 M | 16.7 M | 30 M | 60.9 M | 40.8 M | 66.7 M | 413.8 M | 615.9 M | 1.2 B | 1.7 B | 2.5 B | 2.8 B | 4.1 B | 4.3 B |
| HRMY | 81.5 M | 81.5 M | 81.5 M | 81.5 M | 81.5 M | 81.5 M | 81.5 M | 81.5 M | 81.5 M | (11.6 M) | 97.2 M | 186.5 M | 402.8 M | 467 M | 490.3 M |
Incyte and related stocks such as Alnylam Pharmaceuticals, United Therapeutics, and Ultragenyx Total Stockholder Equity description
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.My Equities
My Current Equities and Potential Positions
| Incyte | INCY |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Delaware; U.S.A |
| Exchange | NASDAQ Exchange |
USD 80.48
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.